Brazil Healthcare Market Analysis
Backed by several factors, such as strong government support and high healthcare demand amongst others are propelling the Brazilian healthcare market to grow at a fast pace. In fact, Brazil can be claimed to be one of the most lucrative healthcare markets in Latin America. Even the Brazilian Government has adopted relevant initiatives and implemented proper plans and policies that resulted in positive development of the overall healthcare services and facilities.
Furthermore, the prevalence of diseases is high in Brazil and the country’s relative affordability factor is also attracting investments in the form of company mergers and setups. Besides, better standards of living in Brazil are also increasing the relative healthcare expenditure in the country. Healthcare spending in the country is expected to grow at a CAGR of around 4.5% during 2011-2014.
The pharma sector in the market has been growing and the generics sector especially has shown tremendous growth over the past years. With several factors, such as increasing patent expiries and greater generic company involvement in Brazil, this segment can be expected to be a main factor for growth of the pharma sector. Innovation and improvements in the medical equipment sector have been consistent in Brazil. The hospitals and primary care sector have also shown promising developments in the industry with greater private sector participation.
The government has been playing a key role in broadening the horizon and revenue patterns of the healthcare industry. With the proper launch of several effective programs, such as Smiling Brazil and UPA 24 Hours, the government has also ensured the better implementation of these kinds of healthcare policies. Investment, management of resources, and awareness building are some of the key goals under such programs. Primary healthcare has been one of the major focus areas, as the country still faces concerns regarding disease prevalence and basic services.
The future outlook of healthcare industry is quite optimistic as companies are investing huge amounts of money in information technology, innovative medical equipments, and clinical research. Health insurance in the country is gaining momentum and has opened opportunities for the private sector as well apart from the government and public insurance facilities. Moreover, world’s leading healthcare providers are looking towards Brazil as an ideal destination for further expansion, as people are becoming more health conscious and there is a large growth potential. In such a scenario, the sector offers significant attraction to several stakeholders, and those participating in the industry developments. The industry is also beset with certain limitations which are covered in the report overcoming which will be of great benefit to the performance of the overall sector.
The report “Brazil Healthcare Market Analysis” covers all the necessary aspects of the Brazilian healthcare market, providing an in-depth research and prudent analysis of the key segments. The segments covered in the report include: Hospital Services Industry, Pharmaceutical Industry, Medical Devices Industry, and Other emerging market segments. The report presents an insight into the current industry trends; key market drivers, and the government initiatives to enable clients understand the market structure and it’s prospective during the forecast period. The report also covers detailed information about the active market players along with their strengths and weaknesses.
Furthermore, the prevalence of diseases is high in Brazil and the country’s relative affordability factor is also attracting investments in the form of company mergers and setups. Besides, better standards of living in Brazil are also increasing the relative healthcare expenditure in the country. Healthcare spending in the country is expected to grow at a CAGR of around 4.5% during 2011-2014.
The pharma sector in the market has been growing and the generics sector especially has shown tremendous growth over the past years. With several factors, such as increasing patent expiries and greater generic company involvement in Brazil, this segment can be expected to be a main factor for growth of the pharma sector. Innovation and improvements in the medical equipment sector have been consistent in Brazil. The hospitals and primary care sector have also shown promising developments in the industry with greater private sector participation.
The government has been playing a key role in broadening the horizon and revenue patterns of the healthcare industry. With the proper launch of several effective programs, such as Smiling Brazil and UPA 24 Hours, the government has also ensured the better implementation of these kinds of healthcare policies. Investment, management of resources, and awareness building are some of the key goals under such programs. Primary healthcare has been one of the major focus areas, as the country still faces concerns regarding disease prevalence and basic services.
The future outlook of healthcare industry is quite optimistic as companies are investing huge amounts of money in information technology, innovative medical equipments, and clinical research. Health insurance in the country is gaining momentum and has opened opportunities for the private sector as well apart from the government and public insurance facilities. Moreover, world’s leading healthcare providers are looking towards Brazil as an ideal destination for further expansion, as people are becoming more health conscious and there is a large growth potential. In such a scenario, the sector offers significant attraction to several stakeholders, and those participating in the industry developments. The industry is also beset with certain limitations which are covered in the report overcoming which will be of great benefit to the performance of the overall sector.
The report “Brazil Healthcare Market Analysis” covers all the necessary aspects of the Brazilian healthcare market, providing an in-depth research and prudent analysis of the key segments. The segments covered in the report include: Hospital Services Industry, Pharmaceutical Industry, Medical Devices Industry, and Other emerging market segments. The report presents an insight into the current industry trends; key market drivers, and the government initiatives to enable clients understand the market structure and it’s prospective during the forecast period. The report also covers detailed information about the active market players along with their strengths and weaknesses.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. HEALTHCARE MARKET OVERVIEW
4. MARKET DRIVERS
4.1 Favorable Demographics
4.2 Epidemiology
4.3 Government Initiatives
4.4 Infrastructure and R&D Investments
5. INDUSTRY PERFORMANCE
5.1 Pharmaceutical Market
5.1.1 Generic and Branded Drugs
5.1.2 OTC Drugs
5.1.3 Import and Export
5.2 Medical Equipment Industry
5.3 Hospital Services Industry
5.4 Primary Care
5.4.1 Oral Health
5.4.2 Family Health
6. MARKET OPPORTUNITIES
6.1 Health Insurance Industry
6.2 Medical Tourism Industry
6.3 Clinical Trials Industry
6.4 Biotech Industry
6.5 Healthcare-IT Market
7. REGULATORY ENVIRONMENT
8. GOVERNMENT HEALTHCARE PROGRAMS
9. INDUSTRY RESTRAINTS
9.1 Tax System
9.2 Substandard Hospitals
9.3 Geographic Disparity for Health Provisions
10. COMPETITIVE LANDSCAPE
10.1 Leading Players
10.1.1 Hospital Services
10.1.2 Pharmaceuticals
10.1.3 Medical Devices
2. RESEARCH METHODOLOGY
3. HEALTHCARE MARKET OVERVIEW
4. MARKET DRIVERS
4.1 Favorable Demographics
4.2 Epidemiology
4.3 Government Initiatives
4.4 Infrastructure and R&D Investments
5. INDUSTRY PERFORMANCE
5.1 Pharmaceutical Market
5.1.1 Generic and Branded Drugs
5.1.2 OTC Drugs
5.1.3 Import and Export
5.2 Medical Equipment Industry
5.3 Hospital Services Industry
5.4 Primary Care
5.4.1 Oral Health
5.4.2 Family Health
6. MARKET OPPORTUNITIES
6.1 Health Insurance Industry
6.2 Medical Tourism Industry
6.3 Clinical Trials Industry
6.4 Biotech Industry
6.5 Healthcare-IT Market
7. REGULATORY ENVIRONMENT
8. GOVERNMENT HEALTHCARE PROGRAMS
9. INDUSTRY RESTRAINTS
9.1 Tax System
9.2 Substandard Hospitals
9.3 Geographic Disparity for Health Provisions
10. COMPETITIVE LANDSCAPE
10.1 Leading Players
10.1.1 Hospital Services
10.1.2 Pharmaceuticals
10.1.3 Medical Devices
LIST OF FIGURES:
Figure 3-1: Healthcare Expenditure (Billion US$), 2009-2014
Figure 4-1: Share of Population Diagnosed with Hypertension (2006 & 2009)
Figure 4-2: Prevalence of Hypertension in Population Aged 65 Years & Above (2006 & 2010)
Figure 4-3: Share of Population with Obesity (2006 & 2010)
Figure 5-1: Share of Brazilian Pharmaceutical Market in Latin America (2010)
Figure 5-2: Pharmaceutical Market (Billion BRL), 2009-2014
Figure 5-3: Pharmaceutical Market (Billion Units), 2008 & 2010
Figure 5-4: Share of Domestic and Foreign Capital in Pharmaceutical Retail Market (2009)
Figure 5-5: Global - Pharmaceutical Market Ranking (2004, 2009 & 2014)
Figure 5-6: Share of Generics in Pharmaceutical Market (2010)
Figure 5-7: Generic Drugs Market (Billion BRL), 2009-2014
Figure 5-8: Generic Drugs Market (Million Units), 2009 & 2010
Figure 5-9: Pharmaceutical Imports (Billion US$), 2008-2010
Figure 5-10: Pharmaceutical Exports (Billion US$), 2008-2010
Figure 5-11: Medical Equipment Market (Billion US$), 2009-2014
Figure 5-12: Medical Equipment Imports (Billion US$), 2008-2010
Figure 5-13: Medical Equipment Exports (Million US$), 2008-2010
Figure 5-14: Number of Doctors (‘000), 2009-2014
Figure 5-15: Dental Schools by Sector (%), 2010
Figure 5-16: Coverage of Community Agents Program (PACS) and Family Health Program (PSF) (%), 2007-2009
Figure 6-1: Private Health Insurance Net Premium (Billion BRL), 2008-2010
Figure 6-2: Number of Clinical Studies (2008-2010)
Figure 9-1: Tax Rate on Medicines in Brazil, Argentina and Germany (%)
Figure 3-1: Healthcare Expenditure (Billion US$), 2009-2014
Figure 4-1: Share of Population Diagnosed with Hypertension (2006 & 2009)
Figure 4-2: Prevalence of Hypertension in Population Aged 65 Years & Above (2006 & 2010)
Figure 4-3: Share of Population with Obesity (2006 & 2010)
Figure 5-1: Share of Brazilian Pharmaceutical Market in Latin America (2010)
Figure 5-2: Pharmaceutical Market (Billion BRL), 2009-2014
Figure 5-3: Pharmaceutical Market (Billion Units), 2008 & 2010
Figure 5-4: Share of Domestic and Foreign Capital in Pharmaceutical Retail Market (2009)
Figure 5-5: Global - Pharmaceutical Market Ranking (2004, 2009 & 2014)
Figure 5-6: Share of Generics in Pharmaceutical Market (2010)
Figure 5-7: Generic Drugs Market (Billion BRL), 2009-2014
Figure 5-8: Generic Drugs Market (Million Units), 2009 & 2010
Figure 5-9: Pharmaceutical Imports (Billion US$), 2008-2010
Figure 5-10: Pharmaceutical Exports (Billion US$), 2008-2010
Figure 5-11: Medical Equipment Market (Billion US$), 2009-2014
Figure 5-12: Medical Equipment Imports (Billion US$), 2008-2010
Figure 5-13: Medical Equipment Exports (Million US$), 2008-2010
Figure 5-14: Number of Doctors (‘000), 2009-2014
Figure 5-15: Dental Schools by Sector (%), 2010
Figure 5-16: Coverage of Community Agents Program (PACS) and Family Health Program (PSF) (%), 2007-2009
Figure 6-1: Private Health Insurance Net Premium (Billion BRL), 2008-2010
Figure 6-2: Number of Clinical Studies (2008-2010)
Figure 9-1: Tax Rate on Medicines in Brazil, Argentina and Germany (%)
LIST OF TABLES:
Table 4-1: Demographic Characteristics (2009-2014)
Table 4-2: Breakup of Obese People by Age Group
Table 5-1: Market Share of Leading Pharmaceutical Companies (2010)
Table 5-2: Leading Drugs by Sales (Million US$)
Table 5-3: Market Share of Leading Generic Companies (2010)
Table 5-4: Healthcare Human Resources (2009-10)
Table 6-1: Cost of Various Surgical Procedures in Comparison to United States (US$)
Table 8-1: Key Goals under Various Parts of UPA 24 Hours Program
Table 10-1: São Luiz - Strengths & Weaknesses
Table 10-2: Sanofi-Aventis - Strengths & Weaknesses
Table 10-3: Bayer - Strengths & Weaknesses
Table 10-4: Novartis - Strengths & Weaknesses
Table 10-5: Pfizer - Strengths & Weaknesses
Table 10-6: 3M - Strengths & Weaknesses
Table 10-7: AGFA - Strengths & Weaknesses
Table 4-1: Demographic Characteristics (2009-2014)
Table 4-2: Breakup of Obese People by Age Group
Table 5-1: Market Share of Leading Pharmaceutical Companies (2010)
Table 5-2: Leading Drugs by Sales (Million US$)
Table 5-3: Market Share of Leading Generic Companies (2010)
Table 5-4: Healthcare Human Resources (2009-10)
Table 6-1: Cost of Various Surgical Procedures in Comparison to United States (US$)
Table 8-1: Key Goals under Various Parts of UPA 24 Hours Program
Table 10-1: São Luiz - Strengths & Weaknesses
Table 10-2: Sanofi-Aventis - Strengths & Weaknesses
Table 10-3: Bayer - Strengths & Weaknesses
Table 10-4: Novartis - Strengths & Weaknesses
Table 10-5: Pfizer - Strengths & Weaknesses
Table 10-6: 3M - Strengths & Weaknesses
Table 10-7: AGFA - Strengths & Weaknesses
